Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

2033 - Effectiveness of topical steroid therapy for prevention of regorafenib-associated hand-foot skin reaction (533P)


18 Nov 2017


Poster lunch


Hiroshi Ishikawa


Annals of Oncology (2017) 28 (suppl_10): x155-x165. 10.1093/annonc/mdx676


H. Ishikawa1, S. Hamauchi2, R. Tanaka1, M. Shino1, K. Yamazaki2

Author affiliations

  • 1 Department Of Pharmacy, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 2 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP


Abstract 2033


Hand-foot skin reaction (HFSR) often hinders completion of regorafenib therapy. No established prophylaxis exists against multikinase inhibitor-associated HFSR and further improvement of prophylaxis for HFSR is needed. Therefore, we offer multiagent therapy to prevent regorafenib-associated HFSR comprising topical steroid (0.05% difluprednate) ointment and 20% urea-based cream.


Subjects were unresectable or recurrent colorectal cancer patients who started regorafenib therapy between May 2013 and March 2014 at the Shizuoka Cancer Center. Electronic medical records were retrospectively examined for HFSR incidence, CTCAE v3.0 grade of severest HFSR, time of HFSR onset, rate of therapy termination, delay and dose reduction.


Subjects were 55 patients and median therapy duration was 7.1 weeks. Overall and grade 3 HFSR incidence rate in this study (73% and 22%, respectively) was lower than in the CORRECT study Japanese subpopulation (80% and 28%, respectively). HFSR (grade ≥2) occurred in the first cycle or later in 42% and 11% of patients, respectively. HFSR accounted for 33% and 61% of first-cycle regorafenib delay and dose reductions, respectively, and HFSR accounted for 40% and 53% in any cycle, respectively.


Effectiveness of prophylactic topical steroids against regorafenib-associated HFSR was shown in this study. Therefore, this prophylaxis is applicable in clinical settings.

Clinical trial identification

Legal entity responsible for the study

SCC retrospective study 743




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.